GP2’s mission is to further understand the genetic architecture of Parkinson’s disease (PD) through genotyping diverse participant groups and studying highly suspected monogenic forms of PD. In support of this mission, we continue to collect diverse cohorts from around the world through collaboration and openly sharing data, processes, and results. Explore the dashboard below to understand our milestones achieved so far, and continue to visit this page as data will be updated monthly.
Total Global Data
Last Updated: May 8, 2023 | Original design by GP2 Hackathon 2021 Team: Mary Makarious, Kajsa Brolin, Yeajin Song, and Anastasia Illarionova
Biological Markers in PD
Number of Samples Completed and Expected
PD samples include clinically diagnosed cases that meet classifying criteria.
Non-PD samples include healthy controls, Prodromal, and Parkinson’s Adjacent Disorders (PAD) which come from related diagnoses and neurological disorders.
Total samples include PD cases, healthy controls, Prodromal cases, and Parkinson’s Adjacent Disorders (PAD).